Pacific Biosciences of California, Inc.
PACB
$1.38
$0.129.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 156.11M | 152.36M | 154.01M | 173.15M | 188.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.11M | 152.36M | 154.01M | 173.15M | 188.87M |
| Cost of Revenue | 113.09M | 114.67M | 110.74M | 123.31M | 134.16M |
| Gross Profit | 43.02M | 37.69M | 43.27M | 49.83M | 54.72M |
| SG&A Expenses | 169.23M | 178.93M | 182.52M | 172.47M | 179.06M |
| Depreciation & Amortization | 381.10M | 386.94M | 27.40M | 27.40M | 21.47M |
| Other Operating Expenses | 5.07M | 5.07M | 998.00K | 3.44M | 3.44M |
| Total Operating Expenses | 778.96M | 812.02M | 462.48M | 478.62M | 512.12M |
| Operating Income | -622.85M | -659.67M | -308.46M | -305.47M | -323.25M |
| Income Before Tax | -526.31M | -657.73M | -309.54M | -394.96M | -411.81M |
| Income Tax Expenses | 49.00K | 14.00K | 316.00K | -718.00K | -11.42M |
| Earnings from Continuing Operations | -526.36 | -657.75 | -309.85 | -394.24 | -400.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -526.36M | -657.75M | -309.85M | -394.24M | -400.38M |
| EBIT | -622.85M | -659.67M | -308.46M | -305.47M | -323.25M |
| EBITDA | -226.91M | -257.05M | -267.28M | -264.15M | -289.13M |
| EPS Basic | -1.79 | -2.29 | -1.14 | -1.46 | -1.50 |
| Normalized Basic EPS | -1.31 | -1.41 | -0.69 | -0.69 | -0.74 |
| EPS Diluted | -1.79 | -2.29 | -1.14 | -1.46 | -1.50 |
| Normalized Diluted EPS | -1.30 | -1.40 | -0.68 | -0.69 | -0.74 |
| Average Basic Shares Outstanding | 1.15B | 1.13B | 1.10B | 1.08B | 1.06B |
| Average Diluted Shares Outstanding | 1.18B | 1.15B | 1.12B | 1.08B | 1.06B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |